Abstract
Prior studies suggest benefits of blood pressure lowering on cardiovascular risk may be attenuated in patients with resistant hypertension compared with the general hypertensive population, but prospective data are lacking. We assessed intensive (<120 mm Hg) versus standard (<140 mm Hg) systolic blood pressure targets on adverse outcome risk according to baseline resistant hypertension status, using Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Systolic Blood Pressure Intervention Trial (SPRINT) patient-level data. Patients were categorized as having baseline apparent resistant hypertension (blood pressure ≥130/80 mm Hg while using 3 antihypertensive drugs or use of ≥4 drugs regardless of blood pressure) or non-resistant hypertension (all others). Cox regression was used to assess effects of treatment assignment, resistant hypertension status, their interaction, and other covariates, on first occurrence of 2 outcomes: myocardial infarction, stroke, cardiovascular death ± heart failure, and the same outcomes plus all-cause death, individually. Among 14,094 patients, 2710 (19.2%) had baseline apparent resistant hypertension. In adjusted models, an intensive target reduced risk of both outcomes (myocardial infarct...Continue Reading
References
Jan 18, 2005·Lancet·Patricia M KearneyJiang He
Jul 12, 2007·The American Journal of Cardiology·UNKNOWN ACCORD Study GroupMark D Sullivan
Apr 9, 2008·Hypertension·David A CalhounRobert M Carey
Mar 17, 2010·The New England Journal of Medicine·William C CushmanFaramarz Ismail-Beigi
Jan 13, 2012·The Journal of Clinical Hypertension·Maria Czarina AcelajadoDavid A Calhoun
Mar 2, 2012·Circulation·Stacie L DaughertyP Michael Ho
Nov 13, 2012·European Heart Journal·Dharam J KumbhaniUNKNOWN REACH Registry Investigators
Feb 16, 2013·Journal of Hypertension·Monika ZygmuntowiczJerzy Chudek
Jun 19, 2013·European Heart Journal·Giuseppe ManciaDavid A Wood
Dec 5, 2013·Journal of Hypertension·Steven M SmithRhonda M Cooper-Dehoff
Mar 4, 2014·Journal of the American Heart Association·Steven M SmithRhonda M Cooper-Dehoff
Jun 7, 2014·Clinical Trials : Journal of the Society for Clinical Trials·Walter T AmbrosiusUNKNOWN SPRINT Study Research Group
Jun 24, 2014·Journal of the American Society of Hypertension : JASH·Marguerite R IrvinDavid A Calhoun
Sep 27, 2014·Hypertension·Paul MuntnerMahboob Rahman
Jun 19, 2015·Journal of Human Hypertension·N W CarrisS M Smith
Sep 29, 2015·Lancet·Bryan WilliamsUNKNOWN British Hypertension Society's PATHWAY Studies Group
Nov 10, 2015·The New England Journal of Medicine·UNKNOWN SPRINT Research GroupWalter T Ambrosius
Feb 10, 2016·The Journal of Clinical Hypertension·Brent M EganAngelo Sinopoli
Oct 18, 2016·Journal of Women's Health·Steven M SmithRhonda M Cooper-DeHoff
Dec 17, 2016·The American Journal of Medicine·Sripal BangaloreUNKNOWN ALLHAT Collaborative Research Group
Sep 25, 2017·Journal of the American Heart Association·Francesca ViazziUNKNOWN AMD‐Annals Study Group
Nov 15, 2017·Circulation·Paul MuntnerPaul K Whelton
Citations
Jun 5, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Nasratullah Wahidi, Alan J Lerner
Jan 10, 2020·Current Hypertension Reports·Wilbert S Aronow
Oct 18, 2019·Current Hypertension Reviews·Guillaume LamiraultNantes University Hospital Working Group On Hypertension
Apr 23, 2020·Future Cardiology·Wilbert S Aronow
Jul 15, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Elena Rodríguez-SánchezGema Ruiz-Hurtado
Feb 6, 2020·Circulation. Cardiovascular Quality and Outcomes·Steven M SmithRhonda M Cooper-DeHoff
Feb 1, 2020·Scientific Reports·Carolina Tosin BuenoPaulo Caleb Junior Lima Santos
Dec 7, 2020·The Journal of Clinical Hypertension·Chan Joo LeeKazuomi Kario
May 27, 2020·Current Opinion in Cardiology·Katherine E Di Palo
Sep 21, 2021·American Journal of Hypertension·Fabio AngeliPaolo Verdecchia